Beam Doses First Patient in BEAM-302 Global Pivotal Trial; Reports Q1
Beam Therapeutics dosed the first patient in the global pivotal cohort of its BEAM-302 trial for AATD and reported $1.2 billion in cash, indicating continued clinical progress and operational strength.
View filing at SEC.gov →